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Objective: Outcome measures are rarely available for surveillance and system 
performance monitoring for mental disorders and addictions. Our study aims to demonstrate 
the feasibility and face validity of routinely measuring the mortality gap in the Canadian 
context at the provincial and regional levels using the methods and data available to the 
Canadian Chronic Disease Surveillance System (CCDSS) of the Public Health Agency of 
Canada. 
Methods: We used longitudinal data from the Quebec Integrated Chronic Disease 
Surveillance System, which also provides aggregated data to the CCDSS. This includes 
data from the health insurance registry physician claims and the hospital discharge abstract 
for all mental disorder diagnoses (International Classification of Diseases [ICD]-9  
290–319 or ICD-10 F00–F99). Patients were defined as having had received a mental 
disorder diagnosis at least once during the year. Life expectancy was measured using 
Chiang’s method for abridged life tables, complemented by the Hsieh method for 
adjustment of the last age interval.
Results: We found a lower life expectancy among psychiatric patients of 8 years for men 
and 5 years for women. For patients with schizophrenia, life expectancy was lowered by 12 
years for men and 8 years for women. Cardiovascular disease and cancer were the most 
common causes of premature death. Findings were consistent across time and regions 
of the province. Lower estimates of the mortality gap, compared with literature, could be 
explained by the inclusion of primary care patients and methods.
Conclusions: Our study demonstrates the feasibility of using administrative data to 
measure the impact of current and future mental health plans in Canada provided the 
techniques can be replicated in other Canadian provinces.
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Un système de surveillance pour contrôler la surmortalité des 
personnes souffrant de maladie mentale au Canada
Objectif : Les mesures des résultats sont rarement disponibles pour le rendement de la 
surveillance et du système contrôlant les maladies mentales et les dépendances. Notre 
étude vise à démontrer la faisabilité et la validité apparente de mesurer couramment les 
disparités de mortalité dans le contexte canadien à l’échelle provinciale et régionale, à 
l’aide des méthodes et des données offertes par le Système national de surveillance des 
maladies chroniques (SNSMC) de l’Agence de la santé publique du Canada.
Méthodes : Nous avons utilisé des données longitudinales du Système intégré de 
surveillance des maladies chroniques du Québec, qui fournit aussi des données 
cumulatives au SNSMC. Ceci comprend des données de facturation des médecins du 
registre de l’assurance maladie et des sommaires des congés d’hôpitaux pour tous les 
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CCDSS Canadian Chronic Disease Surveillance System 
CVD  cardiovascular disease
GP  general practitioner
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INSPQ  Institut national de santé publique du Québec
MHCC  Mental Health Commission of Canada
PHAC  Public Health Agency of Canada 
QICDSS Quebec Integrated Chronic Disease Surveillance  
  System
SMD severe mental disorder
Clinical Implications
• Our results confirm the substantial impact of mental 
illness on mortality.
• The most common causes of death mirror those in the 
general population: CVDs, respiratory diseases, and 
cancers.
• Because of the complex, multi-factorial nature of these 
conditions, multi-pronged approaches, both individual- 
and population-based, will be required to address these 
inequalities.
Limitations
• The cross-sectional method was used to calculate life 
expectancy.
• Administrative data may also be subject to recording 
bias, especially for diagnosis.
• The CCDSS psychiatric case definition differs from 
those for other disorders by stipulating that a person 
must attend for treatment in the current year to be 
considered a prevalent case in that year.
Although first identified 20 years ago, the excess mortality observed in people with mental illness has 
not abated. If anything, the mortality gap has increased 
in the past decade, especially for CVDs.1–3 The 
difference is greatest for patients in contact with specialist 
care and for those with organic brain syndromes, substance 
disorders, or psychoses,2 the latter group dying about 20 
years earlier than their mentally well counterparts.4 Chronic 
physical disorders, such as CVD and cancer, are the main 
causes, accounting for 85% of preventable mortality, 
compared with 15% accounted for by suicide, yet chronic 
physical disorders receive far less attention.5 Reasons for 
increased chronic disorders and unfavourable consequences 
include socioeconomic disadvantages, medication side 
effects, health habits (for example, smoking), and reduced 
access to physical health care.6 Psychiatric patients have not 
benefited from preventive measures that have reduced the 
impact of chronic disorders, such as CVD, in the general 
population. As a result, while mortality rates from ischemic 
heart disease have fallen in the last 20 years, they have 
increased in psychiatric patients, leading to a growing 
disparity in outcomes.2,7 The latter may also be related to 
diagnostic overshadowing; that is, symptoms and signs 
of urgent medical attention being overlooked as part of 
illness behaviour or owing to time pressure in primary and 
specialist medical care toward people with chronic diseases 
and mental disorders.8
In the United Kingdom, Thornicroft9 highlighted the 
need for a public health approach to this problem, using 
the mortality gap as an easy-to-grasp indicator of system 
improvement. The MHCC called for similar performance 
indicators across provinces.10 One approach is the use of 
administrative data in the surveillance of changes in the 
mortality gap and the effect of interventions at clinical, 
programmatic, and system levels.11
Surveillance refers to the ongoing, systematic use of 
such data to identify associations and predictors of 
health outcomes. Surveillance was originally applied to 
communicable diseases but is increasingly being extended 
to mental illness, diabetes, arthritis, cancer, as well as 
circulatory and other diseases. For instance, standard case 
definitions for the surveillance of diabetes have been adopted 
by the CCDSS, a collaborative network of provincial and 
territorial surveillance systems supported by the PHAC.12 
It produces indicators, including mortality indicators. This 
diagnostics de trouble mental (Classification internationale des maladies [CIM]-9 290–319 ou CIM-10 
F00–F99). Les patients ont été définis comme ayant reçu un diagnostic de trouble mental au moins une 
fois durant l’année. L’espérance de vie a été mesurée à l’aide de la méthode de Chiang pour les tables 
de mortalité abrégées, complétée par la méthode de Hsieh pour ajustement du dernier intervalle d’âge. 
Résultats : Nous avons constaté chez les patients psychiatriques une espérance de vie moins élevée 
de 8 ans pour les hommes et de 5 ans pour les femmes. Pour les patients souffrant de schizophrénie, 
l’espérance de vie était moins élevée de 12 ans pour les hommes et de 8 ans pour les femmes. La 
maladie cardiovasculaire et le cancer étaient les causes les plus communes de décès prématuré. 
Les résultats étaient cohérents à travers le temps et les régions de la province. Les estimations 
moins élevées des disparités de mortalité, comparativement à la littérature, pourraient s’expliquer par 
l’inclusion des patients et des méthodes des soins primaires.
Conclusions : Notre étude démontre la faisabilité d’utiliser des données administratives pour mesurer 
l’impact des plans de santé mentale présents et futurs au Canada, si les techniques peuvent être 
reproduites dans d’autres provinces canadiennes
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system is being extended to psychiatric disorders, with the 
first national report recently published,13 based on feasibility 
studies conducted in some provinces.14,15 In Quebec, the 
INSPQ has applied the diagnostic definitions from these 
feasibility studies for the surveillance of mental disorders, 
excess mortality, and service use.16,17
An advantage of the CCDSS is the inclusion of primary 
care where most people with chronic diseases, such as 
diabetes and mental disorders, are treated. Studies that 
have used administrative data from elsewhere, such as 
Italy, Sweden, and the United States, have been restricted 
to patients attending psychiatric services and thus may 
not reflect the mortality experience of most people with 
psychiatric problems.18–20 Therefore, the absolute figures 
of the mortality gap may vary because of the population 
covered, but also the very methods that are applied.
Our study aims to demonstrate the feasibility and face 
validity of routinely measuring the mortality gap for mental 
disorders in the Canadian context at the provincial and 
regional levels, using the methods and data available to 
the CCDSS of the PHAC and building on the surveillance 
activities of the INSPQ and its integrated chronic disease 
surveillance system.
Methods
Data Sources
We used the resources of the public health agency of 
Quebec (INSPQ).17 Estimates were produced using linked 
administrative databases from the physician billing agency 
(Régie de l’assurance maladie du Québec) and the Quebec 
Ministry of Health and Social Services, which together 
make up the QICDSS. About 99% of Quebec’s 7.5 million 
residents were registered with health insurance in 2006. 
We used the following databases: the Health Insurance 
Registry, the physician billing database, the hospitalization 
database, and the Vital Statistics Death Database. Causes of 
death for the mortality study were extracted from the death 
database. The ninth or tenth revisions of the ICD were used 
for coding diagnoses.
Case Definition and Measure of Prevalence
We used the case definition for psychiatric disorders chosen 
by the CCDSS for use in administrative databases and for 
which there are validated case definitions14,15,21; that is, 
any contact with a health service with an ICD-9 diagnosis 
of 290-319 or ICD-10 equivalent. Within this group, we 
defined 2 further categories: mood and anxiety disorders 
(296, 300, 311 in ICD-9 and F30-F48 and F68 in ICD-10) 
and schizophrenic disorders (295 in ICD-9 and F20, F21, 
F23.2, and F25 in ICD-10). The former also represents 
common mental disorders, while the latter epitomizes 
SMDs.
We were interested in measuring treated prevalence, which 
meant that a person had to meet the case definition in a given 
year to be considered as a prevalent case for that specific 
year. Each disease category was analyzed separately, which 
meant that a person, who, for example, had received a 
diagnosis of both a mood disorder and schizophrenia was 
counted in both categories. 
Period Covered, Temporal and Regional 
Comparisons
Estimates were obtained through population-based 
longitudinal follow-up. The analysis period began on April 
1, 1999, and ended on March 31, 2012. Comparisons over 
time and between regions were made using age-adjusted 
measures. These were directly standardized to the age 
structure of the population of Quebec in 2001.
Definition of Excess Mortality and Measure of Life 
Expectancy
Abridged life tables using Chiang’s method were used 
to calculate the life expectancies of people with mental 
disorders by 5-year age groups: 1 to 4 years, 5 to 9 years, 
and so on to 80 to 84 years and 85 years and older.22 An 
abridged life table is a compilation of the death rate for 
each age interval and, for people who died during the age 
interval, the average fraction of life in the interval. The 
Hsieh method was used to adjust the average fraction of life 
in the last interval of the table.23 From these 2 measurements, 
we calculated the probability of death in the interval by 
comparing the number of people living at the beginning of 
the interval with the number of people living at the end of 
the interval. From this, we derived a life expectancy, which 
was calculated during an 11-year period for a more robust 
estimate of mortality. 
Excess mortality rates, overall and stratified by leading 
causes of death, were calculated using risk ratios of age-
standardized mortality rates. Patients were defined based on 
current status in a given year.
Results
Prevalence of Mental Disorders
On average, mental disorders were diagnosed among 12% 
of the population annually. This represented a total of 
903 000 people from 2009 to 2010.16 The age-standardized 
treated prevalence and the number of patients by sex in 
Quebec from 2009 to 2010 for all mental disorders were as 
follows: women: 518 624 (12.7%), men: 381 902 (9.9%); 
for anxiodepressive disorders: women: 369 261 (9.1%), 
men: 211 165 (5.4%); for schizophrenic disorders: women: 
14 242 (0.35%), men: 19 418 (0.50%).
The prevalence of diagnosed mood and anxiety disorders 
and schizophrenic disorders varied little from 1999–2000 
to 2009–2010.16 More than 70% of patients with mood and 
anxiety disorders were only identified and seen by GPs, 
while 75% of patients with schizophrenic disorders were in 
contact with specialist services, as well as GPs.16
Mortality Associated With Mental Disorders
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Figure 1 compares the various regions of Quebec. Life 
expectancy was lowest for people with mental illnesses, 
although the exact extent varied by region. This included 
small regions of less than 100 000 inhabitants, where 
95% confidence intervals were widest. Differences in life 
expectancy between the general population of Quebec 
and people with mental disorders were calculated by sex 
(Table 1). For men with mental disorders, life expectancy 
was 8 years lower than for the general population (70 and 
78 years, respectively). The difference was 4 years for men 
with mood and anxiety disorders (life expectancy = 74 
years), and 12 years for those with schizophrenic disorders 
(life expectancy = 66 years). The life expectancy of women 
with mental health disorders was 5 years lower than for the 
general population (78 and 83 years, respectively). Among 
women with schizophrenic disorders, the life expectancy 
was reduced by 10 years (life expectancy = 73 years). As 
some disorders, such as schizophrenia, occur in young adults, 
analyses were repeated for life expectancy at age 20, with 
similar findings for mental disorders in general, for anxiety 
and depression and for schizophrenia. A separate analysis 
for people who had been psychiatric inpatients indicated a 
greater mortality gap, with a life expectancy of 65 years for 
females (95% CI 63 to 67 years) and 59 for males, (95% 
CI 57 to 60 years), a gap of 18 and 19 years, respectively. 
Compared with the general population, mortality rate ratios 
for mental disorders were higher for all causes of death, 
with suicide and dementia having the greatest differences. 
The pattern was similar when the analyses were restricted to 
patients with SMDs, such as schizophrenia (Figures 2a and 
2b). People with mood and anxiety disorders had similar 
increases in suicide and trauma, but a more ambiguous 
pattern for other causes of death (Figure 2c). However, in 
absolute terms, CVDs and cancers were the main causes of 
death for people with mental disorders (Figure 3).
An analysis of age standardized mortality rates by sex during 
the past decade showed little variation by sex over time, 
suggesting that our estimates of mortality in psychiatric 
patients were stable (Figure 4).
Table 1  Life expectancy at age 1 in the general 
population and in people with mental disorders by 
sex, in Quebec, from 2001–2002 to 2011–2012
Population and 
disease status
Life expectancy, years
Women Men
General population 82.8 77.7
Mental disorders 77.9 69.6
Mood and anxiety 
disorders
83.8 73.5
Schizophrenic 
disorders
72.6 65.5
Figure 1  Life expectancy at age 1 in men and women with and without mental disorders, 
with 95% confidence intervals, in Quebec health regions, from 2001–2002 to 2011–2012
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Interpretation
Our study demonstrates the feasibility of using health 
administrative data for the surveillance of excess mortality 
in patients with severe and common mental disorders in the 
Canadian context. The methods seem robust across mental 
disorders, across regions, and over time.
Our findings emphasize that chronic medical illnesses, 
such as CVDs and cancer, are the most common causes 
of preventable deaths and reduced life expectancy in 
psychiatric patients. Unlike other work from the United 
Kingdom, Sweden, and the United States, our study is 
not restricted to patients of specialist psychiatric services 
but includes all people with a treated psychiatric disorder, 
irrespective of setting, including primary care. This 
reduces referral or selection bias, as most patients receive 
psychiatric treatment from GPs. The only other work that 
included primary care was a 2005 cross-sectional study 
from Nova Scotia.24 However, this work did not use the 
CCDSS definition of mental disorders and did not report 
life expectancy, a metric better understood by decision 
makers and the public. The study also did not include 
data covering a period of 10 years.
Our results confirm the excess mortality of people with 
mental disorders, especially those with the most SMDs, 
such as schizophrenia. However, the reduction in life 
expectancy in our study is less marked than in patients 
of specialist mental health services in the United States, 
Sweden, or Australia.5,18,20,25 One explanation, mentioned 
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Figure 3  Causes of death of people with mental disorders, in Quebec,  
from 2000–2010
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previously, is that we included all patients receiving 
psychiatric care, such as those of family physicians and 
specialists, outside the formal psychiatric care system. This 
explanation is consistent with our own finding that the life 
expectancy of people who had required inpatient treatment 
was significantly worse. Another explanation is that the 
Canada Health Act ensures greater equity than exists in 
other countries, even though discrimination can still occur.26
Similar to some other studies of mood and anxiety 
disorders, we did not find an increased mortality risk for 
CVD and cancer disorders in women.27 This may again 
be related to the inclusion of primary care attenders or 
to greater help seeking behaviour by women with mood 
and anxiety disorders in general, thus enabling earlier 
detection and treatment of comorbid common chronic 
diseases. Nevertheless, considering the association between 
depression and diabetes or other chronic diseases in primary 
care in both sexes, one would expect some reduction in 
life expectancy.28,29 Longer-term and larger-cohort studies 
may reveal significant decreases in life expectancy among 
women, even though this is lower than in men. 
Methodological Limitations
The QICDSS databases only cover people in treatment, and 
one-off surveys have shown that only 40% of Canadians 
with a self-reported mental disorder seek services for their 
mental health.30 However, given that the QICDSS covers 
97% of all insured people, who in turn represent 99% of 
the Quebec population, and that our study extends over 10 
years, this would minimize the likelihood of missing any 
person in the population who received a mental disorder 
diagnosis.17 In addition, one-off surveys can underestimate 
the treated prevalence by one-half. For example, 1 study 
that used the equivalent of the QICDSS databases but 
also took into account procedure codes for talk therapies 
estimated that, each year, 75% of the expected 1-in-5 
people with a mental disorder was identified by GPs.31 In 
the case of schizophrenia, the QICDSS yearly prevalence 
was comparable with the median found in the meta-analysis 
of Saha et al.32
The cross-sectional method was used to calculate life 
expectancy. This is the life expectancy we would obtain if 
a person aged 1 was subjected throughout their life to the 
same age-specific mortalities prevailing in the study period. 
For the subcategory we refer to as having a mental disorder, 
we assume that its life course mortality is equivalent to that 
of mortality levels observed for each age group during our 
study period. Therefore, caution is needed when interpreting 
it as a life expectancy at age 1 for people identified with 
mental disorders. In fact, the measure represents the mean 
number of years left to live beyond the age of 1 for people 
subjected to the mortality conditions of active treated cases 
of mental disorders during the study period.
Administrative data may also be subject to recording bias, 
especially for diagnosis. Although 95% of billing claims 
made by psychiatrists in Quebec include a diagnosis,17 
evidence from Ontario suggests that accuracy is lower 
for substance abuse and disorders other than psychoses.33 
Elsewhere, a study34 from Saskatchewan comparing 
anxiety or mood disorder diagnoses and the prescription 
of antidepressants reported a sensitivity of 84% and a 
specificity of 90%. Therefore, we have emphasized overall 
psychiatric morbidity, or large categories validated in 
previous feasibility studies in some Canadian provinces 
including Quebec,14,15,21 to minimize possible bias. In terms 
of mortality, concordance between the vital statistics death 
database and the physician billings database improved from 
95% to 98% between 1996 and 2009.17
The CCDSS psychiatric case definition differs from those 
for other disorders by stipulating that a person must attend 
for treatment in the current year to be considered a prevalent 
case in that year. In the case of diabetes and hypertension, 
a case is considered to be active until the end of the study 
period, death, or emigration.12,35 Hence deaths of people 
who have been diagnosed with mental disorders in the past 
but have had no diagnosis in the current year were classified 
as not having mental disorders. The impact of these people 
on the measurement of excess mortality is impossible to 
determine, as we do not know the current state of their 
unobserved mental health.
The lack of information in administrative data on services 
delivered outside the province can also be a limitation for 
interregional comparisons. For Quebec, these include areas 
bordering Ontario or New Brunswick, where part of the 
population receives medical care in the adjoining province.
Implications
Our results show the substantial impact of mental illness 
on mortality. Unlike one-off surveys, they present a 
longitudinal picture and thus the ability to evaluate the 
effect of future interventions on the excess mortality faced 
by psychiatric patients. The most common causes of death 
mirror those in the general population: CVDs, respiratory 
diseases, and cancers.
Because of the complex, multi-factorial nature of these 
conditions, multi-pronged approaches will be required 
to address these inequalities, in the same way that multi-
pronged approaches have been used to reduce the mortality 
associated with these common conditions in the general 
population. These strategies should include both individual- 
and population-based components.
In terms of subcategories of psychiatric patients, the 
greater all-cause mortality in schizophrenia may suggest 
discrimination in access to the prevention and treatment 
of chronic diseases, and the need to integrate primary and 
specialist care in the case management and rehabilitation 
of patients who are severely mentally ill.2,26 This might 
include training modules for GPs concerning chronic 
disease comorbidities, taking into account diagnostic 
overshadowing and stigma.9 By contrast, the increased rates 
of suicide and trauma in mood disorders may suggest the 
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need for population-based suicide prevention strategies and 
improved access to psychiatric treatment.36,37
We believe that mental health surveillance will help prompt 
action to improve outcomes at various levels. At a systems 
level, for instance, indicators on diabetes from the CCDSS 
have informed recommendations for system and practice 
improvement.38,39 Similar projects could easily integrate 
mental disorder indicators. For example, mental health 
indicators produced by the PHAC could inform the work of 
national commissions, such as the MHCC.40 This could be 
complemented by the introduction of peer-support workers 
in mental health services and the participation of families in 
governance and system evaluation.41 The development of 
mental health surveillance can be based on such examples 
and integrate indicators on excess mortality to provide 
useful information to guide decision making at program, 
regional, or system levels.
Conclusions
Decreasing discrimination in health and health care services 
for patients with mental illness also requires a public health 
perspective provided by the surveillance and analysis of 
excess mortality among patients with mental disorders,9 
and those with other common chronic disorders. Our study 
demonstrates the feasibility of using administrative data 
to measure the impact of current and future mental health 
plans in Canada, provided the techniques can be replicated 
in other Canadian provinces.10,42
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